Literature DB >> 22106693

Effects of uvulopalatopharyngoplasty: a seven year review.

W H Aneeza1, M B Marina, M Y Razif, N A Azimatun, A Asma, A Sani.   

Abstract

To review the long term outcome of Uvulopalatopharyngoplasty (UPPP) for obstructive sleep apnoea syndrome in a tertiary referral centre. 38 records were traced where UPPP was done from July 2000 to December 2007. 14 patients were followed up for one to seven years where the Epworth sleepiness scale was scored, long term side effects documented and post operative muller's manoeuvre done. Success of UPPP is defined as a reduction in apnoea hypopnea index (AHI) more than 50%. Sixty percent (60%) were successfully treated with UPPP in the long term. Mean ESS was significantly reduced from 12 +/- 6 to 7 +/- 4. 11 out of 14 patients (78.5%) were reported to develop long term side effects of UPPP, the highest being velopharyngeal insufficiency (42.8%). In conclusion, UPPP is effective in improving symptoms of OSA in the long term. However, in view of its side effects, uvula preserving surgery should be considered as a surgical option.

Entities:  

Mesh:

Year:  2011        PMID: 22106693

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  3 in total

1.  Double uvula in a fifty-six-year-old woman.

Authors:  Tolgahan Catli
Journal:  Iran Red Crescent Med J       Date:  2014-12-25       Impact factor: 0.611

Review 2.  Reconsidering first-line treatment for obstructive sleep apnea: a systematic review of the literature.

Authors:  Brian W Rotenberg; Claudio Vicini; Edward B Pang; Kenny P Pang
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-04-06

3.  Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.